Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Women's Health Rheumatology Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Clinical Trial ● Currently Recruiting NCT06450418

Digital App for Speech & Health Monitoring

Digital App for Speech & Health Monitoring — Recruiting • Neurology • NCT06450418.

📅 10 Sep 2026 ⏱ 2 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
NCT ID
NCT06450418
Sponsor
University of Edinburgh
Start
2024-07-12
ClinicaliQ Trial Snapshot
  • Digital App for Speech & Health Monitoring — Recruiting • Neurology • NCT06450418.
  • What is being tested: A smartphone application that uses digital technology to record and analyse speech patterns in patients with neurodegenerative conditions (dementia, MND, MS, and Parkinson's disease) to detect and monitor speech deterioration.
  • Patient eligibility overview: The trial recruits adults diagnosed with neurodegenerative conditions who experience speech problems, with the ability to use smartphone technology and provide informed consent for speech data collection and analysis.
Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

Many people living with neurodegenerative conditions like dementia, motor neuron disease (MND), multiple sclerosis (MS), and Parkinson's disease (PD), suffer from speech problems. Using common digital technologies such as smartphone apps, the investigators can record and analyse speech in detail to provide new information for people living with these conditions, researchers, and healthcare professionals. This study will investigate the use of these digital speech recordings to help diagnose and monitor these conditions. To take part, participants will have either a diagnosis of dementia, motor neuron disease, Parkinson's disease or Multiple…

Eligibility Snapshot
  • - Any one of the following: * A person with a diagnosis of Motor Neuron Disease, Dementia, Multiple Sclerosis, or Parkinson's Disease. * A relative or carer of the above who does not report to have a neurological condition. * A healthy volunteer who does not report to have a neurological condition.

Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Clinical Brief
Smart beds and motion sensors – is this the future of dementia care?
Neurology · BBC Health · 20 Sep 2026
Key takeaways for clinical practice: Smart home technology including motion sensors, bed monitors, and wearable devices (socks) can enable remote monitoring of…
View brief →
Clinical Brief
My daughter has childhood dementia and may not live past 16
Neurology · BBC Health · 01 Apr 2026
Key Clinical Takeaways Childhood dementia represents a group of rare progressive neurodegenerative disorders with devastating outcomes—Sophia's case illustrates the severe functional decline…
View brief →
Guideline
Mirdametinib for treating symptomatic and inoperable plexiform neurofibromas associated with neurofibromatosis type 1 in people 2 to 17 years
Neurology · 16 Sep 2026
Mirdametinib is indicated for symptomatic and inoperable plexiform neurofibromas in children aged 2-17 years with neurofibromatosis type 1 (NF1); confirm diagnosis and…
View guideline →
Guideline
Dementia: Assessment, Management and Support (NICE NG97)
Neurology · 25 Mar 2026
Use cognitive testing (MMSE or MoCA) combined with appropriate imaging to confirm dementia diagnosis • Prescribe acetylcholinesterase inhibitors (donepezil, rivastigmine, or galantamine)…
View guideline →
Guideline
Software with artificial intelligence (AI)-derived algorithms to help interpret electroencephalograms (EEGs) for suspected epilepsy: early-use assessment
Neurology · 01 Oct 2026
AI-assisted EEG interpretation software can support clinicians in identifying abnormalities suggestive of epilepsy, but should complement rather than replace expert clinical review—use…
View guideline →
Clinical Brief
Anaemia and the new dementia link
Neurology · BBC Health · 07 May 2026
Key Takeaways for Clinical Practice Anaemia has been identified as a newly recognised risk factor for dementia, suggesting haemoglobin levels should be…
View brief →